Abstract: Publisher Summary This chapter discusses the eradication of tumor by adoptive transfer of cytotoxic T lymphocytes. Complete and permanent eradication of tumors by histocompatability complex (MHC) class I restricted CD8 + tumor-specific cytotoxic T lymphocytes (CTLs) can be achieved in a variety of experimental murine models. In human metastatic melanoma, CD8 + tumor-specific CTLs are probably therapeutically the most active components among lymphokine-activated killer or tumor-infiltrating lymphocytes cells, with a possibly important contribution by CD4 + cells in some patients, although no clinical experience with cloned T cells exists as yet to evaluate this point. Cancer cells can avoid the induction of and destruction by tumorspecific CTLs in a number of ways, some of which can be manipulated to increase the efficacy of sensitization or adoptive therapy. T cell therapy allows targeting on minute changes in any cellular peptide that is presentable in the context of MHC molecules. CD8 + CTLs stand out as remarkably effective in tumor eradication in view of their remarkable potency, and specificity in allograft rejection and antiviral immunity.

Abstract: Publisher Summary This chapter discusses the role of transforming growth factor- α (TGF- α) in the proliferation of the normal cells and its potential importance in tumor development. Research during the past few years had made it evident that TGF- α plays a role in the physiology of the normal cells and tissues. All types of normal epithelial cells synthesize TGF- α. These cells have TGF- α receptors, thus making them responsive to the action of TGF- α in an autocrine fashion. Even though there no direct proof in vivo, it is likely that a normal role of the endogenous TGF- α synthesis in these epithelia is to drive their proliferation. The effect of TGF- α on substrate-dependent colony formation of human keratinocytes has been studied in detail. TGF- α is a normal physiological ligand of the TGF- α receptor that plays a role in cellular proliferation not only in the adult, but presumably even more importantly in organ and tissue development. Its role in normal tissues certainly does not exclude a role in the establishment and maintenance of the malignant character of the tumor cells. TGF- α plays a role in and contribute to phenotypic transformation and stimulates the proliferation of the tumor cells and of the tumor in vivo. TGF- α expression influences the invasive behavior of the tumor cells and contributes to the induction of neovascularization of the tumors and to the malignancy-induced hypercalcemia.

Abstract: Publisher Summary This chapter presents an integrated account of a genetic approach to the identification of tumor rejection antigens that has been pursued mainly in the laboratory. These results are presented in the context of the present understanding of antigen recognition by T lymphocytes. Considerable progress has been achieved recently in our understanding of antigen recognition by T lymphocytes. The major histocompatibility complex and the structures of its major protein products are known with a remarkable degree of precision both for mouse and for humans. Several viral antigens that induce tumor rejection have been identified with a great degree of precision because purified viral proteins and genomes are readily obtained. Biochemical fractionations of the tumor cell extracts in order to obtain purified tumor rejection antigens have been attempted. The fractions were tested for their ability to immunize mice so as to make them resistant to tumor challenge. The chapter focuses on the possibility of using a direct genetic approach to identify tumor rejection antigens encoded by the cellular genome. It describes the analysis of the genes coding for these antigens and its implications for T cellmediated immune surveillance, and a similar analysis of a gene coding for a tumor rejection antigen has been described.

Abstract: Publisher Summary This chapter discusses the mechanics of genomic instability and the way the phenotype of genomic instability predisposes to cancer and accelerates tumor progression. The large number of genomic instability genes suggests that the probability of some people in the human population carrying a recessive mutation in a genomic instability gene is high. Cell size and cell death affect the number of genomic instability mutations that are expected in a tumor. The impact of individual genomic instability mutations on tumor progression is dependent upon active cell division. Some examples of disruption of these pathways leading to genomic instability are also considered in the chapter by a selective survey of cellular mechanisms involved in maintaining genomic stability. The large number of components involved in those mechanisms may increase the likelihood that disruption of normal genomic stability mechanisms will occur during a normal lifespan and during the growth of benign neoplasms. Various factors that can affect the frequency of genomic instability mutations are also considered in the chapter. These mechanisms suggest ways to delay or prevent certain types of cancer. The genomic alterations identified in human cancers can be viewed by cellular pathways dedicated to the maintenance of genomic stability.

Abstract: Publisher Summary This chapter explores and compares different possible mechanisms by which hepadnaviruses maytrigger liver cell proliferation and transformation, and considers the factors that may influence the primacy of some oncogenic pathways over others in tumors induced by different viruses of the same family. Primary hepatocellular carcinoma (HCC) is one of the most common cancers in many parts of the world and is also one of the rare human cancers showing seroepidemiologic association with a viral infection. The role of hepatitis B virus (HBV) as a causal agent of HCC is established and the increased risks of developing HCC are estimated. Productive HBV infections potentiate the action of exogenous carcinogenic factors like aflatoxins and alcohol. The clinical and immunological aspects of HBV infections and their modes of transmission are also discussed as are genetic organization of the HBV genome, genome structure and replication, and regulated expression of viral genes. HBV DNA integration patterns into host-cell DNA have led to a different hypothesis on the contribution of HBV to hepatocarcinogenesis. Hepatitis B is rendered highly contagious by the unusual stability of infectious HBV virions present in the blood and other body fluids like saliva, urine, and semen.

Abstract: Publisher Summary This chapter discusses the role of Raf-1 phosphorymtion in signal transduction. Raf-1 has a central role in the signal transduction pathways of all growth factors. Its serine/threonine protein kinase activity is increased following the stimulation of most growth factor receptors. The activation is accompanied by phosphorylation on serine and, in some cases, on tyrosine, and threonine residues. When activated, Raf-1 is transiently associated with a signaling complex formed around the activated growth factor receptor that contains several secondary messengers, the commonly found so far being GTPase-activating protein, proteins-phospholipase C-y, and PI-3’ kinase. The composition of the complex varies depending on the growth factor receptor. These findings are reminiscent of the combinatorial nature of transcriptional complexes regulating gene expression. It will be illuminating to see what sites on Raf-1 are modified, and what substrates Raf-1 recognizes and phosphorylates in consequence. Several immediate early genes are regulated by signals transmitted through Raf- 1; eventually the signaling cascade converge in the activation of the cdc2 complex possibly by inducing one of the cell cycle-specific cyclins.

Abstract: Publisher Summary Immunization with tumor cells or tumor extracts preventing the growth of subsequently grafted cells provided the proof for immunogenicity of some animal tumors. The demonstration of antigenicity of experimental tumors and the beneficial effects of immunotherapy in animal models generated great expectations for cancer treatment. Active specific immunotherapy in patients was attempted by several investigators using various vaccines such as irradiated autologous tumor cells allogeneic or extracts of the corresponding histologic type. This chapter discussesthe potential of the combined treatment modalities including tumor debulking, followed by active immunization with tumor material, and by administration of cytokines, other biological response modifiers (BRMs), and antitumor antibodies in various combinations. The new ideas for immunotherapy propose readministration of autologous tumor–reactive T cells transfected with cytokine–encoding genes, and the use of encapsulated cytokines directed by antibodies to the tumor cells. These may home in on the tumor tissue and deliver large quantities of cytokines. The therapeutic efficacy of these two modalities is not yet known.

Abstract: Publisher Summary Wilms' tumor presents a genetic pattern that may be intermediate in complexity, between the single-locus disease exemplified by retinoblastoma and the multistep tumorigenesis model proposed for colon cancer and other adult tumor types. It constitutes 10% of all pediatric cancers and is the most common intra-abdominal solid tumor in children. It can present a common sporadic and a rare hereditary form, along with various congenital abnormalities. The existence of both gross chromosomal abnormalities as well as more subtle molecular deletions has led to the genetic characterization of a number of loci involved in the development of Wilms' tumor. This chapter discusses the complex genetics of Wilms' tumor and the initial studies characterizing the role of the WT1 gene product in tumorigenesis. Wilms' tumor is very sensitive to chemotherapy. The genetic events underlying the development of Wilms' tumor are complex and the isolation of the WT1 gene has provided an initial molecular key to decipher this process. In Wilms' tumor, the prophetic model that Knudson and Strong had proposed based on epidemiologic analyses has stood the test of time and continues to provide a unifying theme for the molecular study of human neoplasia.

Abstract: Publisher Summary The protein tyrosine kinases (PTKs) are a thematic protein family––built around a highly conserved domain capable of phosphorylating protein substrates on tyrosine residues. Members of this family are made up as a mosaic of sensory, regulatory, and effector domains. Members of the receptor tyrosine kinases (RTK) family hold a number of structural features, such as an extracellular ligand-binding domain, a single transmembrane domain, a single protein tyrosine kinase domain, and one regulatory domain, which serves to reign in the catalytic activity of the PTK domain. This chapter discusses the structure of RTK, its developmental mutants, and tumorigenesis. The expression patterns of many human, murine, and Drosophila RTKs have been determined by Northern analysis of mRNAs from adult tissues. RTKs have been detected at elevated levels in particular types of tumor. RTKs may be overexpressed or inappropriately expressed in a ligand-independent activated form to transform cells. The chapter also reviews several aspects of the oncogenicity of members of the RTK family and the signal transduction pathways downstream of the activated receptor. The structural alterations associated with the acquisition of oncogenicity by members of RTK class of proteins are also focused in the chapter.

Abstract: Publisher Summary Protein 53 (p53) is a normal cellular protein bound to the viral transforming oncogene large-T antigen. Mutations in p53 are the most common genetic changes in human cancer. This chapter discusses the normal and abnormal functions of p53 ,its role in primary breast cancer, and the potential therapeutic implications.. p53 could immortalize or transform primary cells in culture and also demonstrate a cooperation with other oncogenes which suggests it as a dominant transforming oncogene. It is a nuclear protein with putative roles in DNA replication, transcription, and cell cycle control. The mutations in p53 and interactions with viral proteins and the loss of heterozygosity is the common observation in human breast cancer. Depending on the predisposing factors, different mutations in p53 are found in different types of cancer. Several groups have analyzed loss of heterozygosity on chromosome 17p in breast cancer. There are two loci on chromosome l7p––one at p53 and one at locus YNZ–22––which are commonly deleted. Several breast-tumor mutations are now sequenced and there is a good correlation of immunochemistry with mutated p53. If p53 had a role early on in the differentiation of breast cancer, then mutations in p53 could trap cells in a proliferating phase.

Abstract: Publisher Summary This chapter discusses the regulation of major histocompatibility complex (MHC) Class I expression in tumors and explores the oncogenes involved. The molecular mechanism of MHC Class I regulation and possible mechanisms for the action of the myc oncogenes in the down-modulation of MHC Class I expression are also discussed in the chapter. The implication of the suppression of MHC Class I by myc genes for the immune sensitivity of tumor cells and the possible mechanisms underlying it are also considered in the chapter. Members of the myc oncogene family are expressed in all vertebrate cells, where they play a key function in the regulation of growth and differentiation. Their expression increases at the onset of cell proliferation. In animal as well as in human tumor cells, the activation of certain oncogenes largely influences the expression of MHC Class I. Although the precise biological function of the coupling between c–myc expression and MHC Class I expression in normal cells is not known, this phenomenon may provide a mode of immune surveillance against tumor cells with activated myc genes.

Abstract: Publisher Summary This chapter focuses on the biochemical activities controlled by G protein-coupled receptors. It provides an overview on signal transduction mechanisms activated by receptor tyrosine kinases in order to highlight the processes that are controlled by both types of pathways. The chapter illustrates the present knowledge concerning intracellular mechanisms of signal transduction, active shortly after receptor stimulation, in a typical fibroblast or smooth muscle cell. It is necessary to point out the important role of growth factors activating receptor tyrosine kinases. Many studies now converge to indicate that these agents are “master growth factors,” whereas hormones acting through G protein-coupled receptors are merely able to potentiate their action. All known virus-endoced oncogenes that have evolved as efficient stimulators of the host cells' replicative machinery, code for growth factors activating receptor tyrosine kinases, modified receptor tyrosine kinases, or regulatory proteins normally controlled in some way by receptor tyrosine kinases. No viral oncogenes have been found to encode G protein-coupled receptors, G protein subunits, or phospholipases. Potent growth factors such as α-thrombin do not exert their action exclusively through known G protein- mediated pathways but activate other signals as well that may include, at some level a tyrosine kinase activity. Cells that are stimulated to divide by the activation of a G protein-coupled receptor alone carry alterations activating regulatory elements normally employed by receptor tyrosine kinases.

Abstract: Publisher Summary Epstein-Barr virus (EBV) is a herpesvirus that infects all human populations. It is carried in “latent” form in peripheral blood B lymphocytes and is shed in the form of virus particles from a site in the oropharynx. This chapter discusses the expression and function of EBV genes during latency. EBV transforms the B lymphocytes of humans and other primates to continuous proliferation in culture, a process called immortalization. The resultant, latently infected lymphoblastoid cell lines (LCLs), support a predominantly latent viral life cycle in which only a few of the 100 or so viral genes are expressed. Viral genes expressed during latency are candidate immortalizing genes. Of all the viral gene products of the latent cycle, function has been demonstrated most clearly for Epstein-Barr nuclear Antigen 1 (EBNAl). The chapter discusses the structure of viral transcripts and promoters for the EBV latent genes and perspective on viral gene expression in the LCL model. The discovery that EBV in BL tumors expresses only EBNAl clearly limits the applicability of the LCL model to other situations. RNA from BL biopsy material and from group I BL cell lines is clearly the focus of study. Information from such studies, particularly the structure of EBNA 1 -expressing transcripts, could aid polymerase chain reaction studies of viral gene expression in peripheral blood B lymphocytes from healthy seropositive individuals.

Abstract: Publisher Summary This chapter presents the accumulated data from the molecular genetic analyses of human central nervous system (CNS) tumors and compares these data with the tumor evolution model of Nowell by using the histopathologically assessed malignancy of such tumors as an indicator of their stage of malignant progression. The chapter considers the level of resolution that has been obtained toward understanding the molecular genetic nature of CNS neoplasia and the significance of the molecular genetic research toward the clinical diagnosis and treatment of such tumors. The histopathological indicators of biological aggressiveness have been empirically determined through the comparison of tumor morphology with corresponding patient clinical outcome. The chapter describes investigations that represent preliminary attempts toward the identification of genes whose alteration is causally associated with the development of CNS neoplasia, toward the characterization of such alterations, and toward understanding the functional and biological consequences of such alterations. The characterization of genetic changes that confer the tumor cells with increasing growth advantage exposes the mechanisms of cellular proliferation; understanding such processes is the fundamental to altering them and providing promise for the management of CNS cancer.

Abstract: Publisher Summary The cytotoxic T lymphocyte (CTL) is a powerful component of the immune response. This chapter discusses the evidence for immune surveillance and the strategies by which target cells escape CTL recognition. The specificity that targeted viruses and cells have developed strategies to escape recognition implies strong selective pressure in vivo and indicates that these cells exert a major protective role for the host. They explore cell surfaces, monitoring major histocompatibility complex (MHC) class I molecules with their inserted peptides. Self–reactive CTLs are deleted or energized. Those that bind above a threshold affinity to class I molecules containing foreign peptides react vigorously and destroy those cells. The diversity of a class I molecule ensures that the species can cope with most foreign invaders and probably most mutant-self proteins. However, some mutant proteins may fail to evoke an immune response because no new peptides are inserted into class I human leukocyte antigen (HLA) molecules. A CTL response is stimulated but cells of viruses escape CTL recognition which is an important part of tumorigenesis.

Abstract: Publisher Summary This chapter discusses the molecular and genetic characterization of human tissue tumors. Tumor development is a multistep process requiring the mutation of several genes for the expression of the fully malignant phenotype. Soft-tissue is a nonepithelial extraskeletal tissue of the body exclusive of the reticuloendothelial system, glia, and supporting tissue of various parenchymal organs. Soft-tissue tumors are a heterogeneous group of tumors that arise as soft-tissue masses and usually exhibit the differentiated features of adult soft tissue. The major histogenic categories of malignant soft-tissue tumor include leiomyosarcoma, rhabdomyosarcoma, liposarcomas, and malignant peripheral nerve sheath tumors. The development of the human soft-tissue tumors are unknown but a variety of causes have been suggested, including exposure to chemical carcinogens and radiation, physical trauma, immunological factors, and constitutional genetic abnormalities. Major changes in the classification of soft-tissue sarcomas and improvements in diagnosis through the use of new immunohistochemical reagents and refinements in ultrastructural analysis have been made. Some common occurring tumors are fibromatosis, Li–Fraumeni syndrome, Von Recklinghausen's Neurofibromatosis, sarcoma in retinoblastoma families, Beckwith–Wiedemann syndrome, and benign tumors. The tumor etiology, genetic susceptibility to soft-tissue tumors, gene amplification, and chromosomal abnormalities are also discussed in the chapter.

Abstract: Publisher Summary Zilber's contribution to virology is regarded as fundamental The general biological significance of the virogenetic theory was that the principle of integration of viral genomes and cells laid the basis for the malignant transformation of normal cells into malignant ones This principle was valid for all tumors induced by viruses and was later validated after the discovery of integration of retroviruses through reverse transcription and the discovery of the possible etiological role of such viruses as human T-cell leukemia virus, human papilloma virus (HPV), Epstein–Barr virus, and hepatitis B virus (HBV) in certain human neoplasias Although the integration of genomes is necessary, it is far from being sufficient for malignant transformation Only a part of viral genome is necessary for the malignant transformation of cells The integration of the genetic material of a virus and a cell was fully confirmed, and then led to the identification of viral oncogenes, responsible for the process of malignant transformation The virogenetic theory of the origin of tumors became a stepping stone to contemporary virology and experimental oncology

Abstract: Publisher Summary This chapter discusses the molecular mechanisms by which v–erbA potentiates transformation and influences the growth requirements of cells in the context of normal c–erbA /thyroid hormone receptor function. Thyroid hormones reveal or induce the activating function of protooncogene c–erbA , causing the respective genes to be transcribed at maximum efficiency and allowing the differentiation to proceed. The c–erbA acts as a growth suppressor since the resulting differentiated cells irreversibly lose proliferative potential. c-erbA implicates with growth suppressor genes––if both alleles of the c–erbA gene are inactivated, the result would be a loss of hormone responsiveness and most likely a failure of the cells to differentiate. If one allele is converted by somatic mutation into a dominant negative version, differentiation would be blocked and the cells would be free to proliferate. Both the activation of c–erbA as a dominant negative similar to c–erbA , and the loss of function by inactivation of both alleles might be involved in neoplastic transformation. There are somatic mutations that inactivate the c–erbA gene or convert one allele into a dominant negative derivative. The chapter also discusses the c–erbA regulation of erythroid differentiation and gene expression and the structural differences between c–erbA and v–erbA.

Abstract: The skeletal muscle cell system provides a powerful model for exploring the mechanistic basis for the antagonism between cell growth and differentiation. The recent identification of the MyoD family of muscle-specific transcription factors now offers opportunities to dissect at the molecular level of the mechanisms through which defined cell type-specific transcription factors can activate an entire differentiation program as well as to unravel the mechanisms through which growth factor and oncogenic signals can disrupt cellular differentiation. Because the mechanisms for growth factor signaling and induction of cell proliferation are conserved in diverse cell types, it is tempting to speculate that the molecular mechanisms responsible for the antagonism between cell proliferation and differentiation in muscle cells are also operative in other cell types. Resolution of this question, however, must await identification of the regulatory factors that specify cell fate in other lineages.

Abstract: Publisher Summary Lysosomes are membrane-enclosed cytoplasmic organelles, which posses an acidic interior that contains many hydrolytic enzymes. Their major function is in the the degradation of macromolecules, which may be cellular or foreign in origin. This chapter discusses the properties of lysosomes and their enzymes that are relevant to malignancy. Lysosomal hydrolases are synthesized and glycosylated in the rough endoplasmic reticulum. Lysosomes play an important role in the malignant process. Aspects of carcinogenesis, invasion and metastasis, and shrinkage of neoplasms in response to therapy have all been attributed to lysosomes or their products. Lysosomes can be studied by several methods, such as by ultracentrifugation isolation, enzyme activity assay, histochemical techniques, and electron microscopy. The activity of lysosomal enzymes in human tumors is compared to the normal tissue of origin. Elevation in the serum level of lysosomal enzymes is reported in both cancer patients and tumor-bearing animals. Lysosomal enzyme activity is estimated in different regions of tumors. Lysosomal enzymes are associated with invasiveness and metastatic potential in some experimental tumors. Lysosomes play a role in the uptake, processing, or efflux of some cytotoxic agents and might provide mechanisms leading to some forms of drug resistance.